Thermo Fisher Scientific (TMO) has been active on the product front, rolling out the Gibco CTS Compleo Fill and Finish System, the CHOvantage GS Cell Line Development Kit and the Glacios 3 Cryo TEM in quick succession.
See our latest analysis for Thermo Fisher Scientific.
Despite the string of product launches and recent collaboration news, Thermo Fisher Scientific’s 90 day share price return of 17.05% and year to date share price return of 17.05% point to fading momentum, even though the 1 year total shareholder return of 4.94% remains slightly positive.
If these biotech tools and cell therapy launches have caught your attention, it could be a good moment to widen your search with a screener focused on 37 healthcare AI stocks
With Thermo Fisher shares delivering a 17.05% decline over 90 days, while trading at a small intrinsic discount of about 4% and a 34.58% discount to analyst targets, is there still a buying opportunity here or is future growth already priced in?
Most Popular Narrative: 9% Undervalued
Thermo Fisher Scientific’s last close of $491.46 sits below the narrative fair value estimate of $540.27, framing the stock as modestly undervalued by that lens.
Resilient Demand for Life Sciences & Diagnostics: TMO is a key supplier for biotech, pharma, and research institutions, ensuring steady demand despite economic cycles.
Recurring Revenue Model: A significant portion of revenue comes from consumables and services, providing stability and reducing cyclicality.
Want to see what keeps this fair value above the current price? The narrative leans on steady top line progress, firmer margins, and a future earnings multiple that assumes Thermo Fisher keeps its position as a core supplier to global research and pharma.
According to Unike, the narrative backing the $540.27 fair value leans on a blend of mid single digit revenue expansion, higher profitability as services scale, and a P/E assumption that reflects Thermo Fisher’s role across life sciences, diagnostics, and contract research.
Result: Fair Value of $540.27 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this story can change quickly if biotech R&D budgets tighten or if a large acquisition like PPD fails to deliver expected cost and margin benefits.
Find out about the key risks to this Thermo Fisher Scientific narrative.
Next Steps
If this mix of potential risks and rewards feels finely balanced, consider taking time now to review the details yourself and weigh both sides with the 5 key rewards and 1 important warning sign.
Ready to widen your opportunity set?
If you stop at a single stock, you might miss ideas that fit your goals even better, so use tools that help you compare and filter quickly.
- Spot potential bargains early by scanning screener containing 25 high quality undiscovered gems and see which under followed names match your preferred fundamentals.
- Strengthen your defense by checking 67 resilient stocks with low risk scores where companies score well on resilience and financial risk.
- Build a sturdier core by reviewing the solid balance sheet and fundamentals stocks screener (39 results) and focus on businesses backed by healthier balance sheets.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com